Regular Article
The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo [a] in hypopituitary adults previously treated with conventional replacement therapy

https://doi.org/10.1054/ghir.1999.0102Get rights and content

Abstract

Hypopituitary adults receiving conventional hormone replacement therapy are reported to have increased cardiovascular mortality. Previous studies indicate that these patients have several abnormalities in lipoprotein metabolism, including reduced low density lipoprotein (LDL) uptake and impaired metabolism of triglyceride-rich lipoproteins. The effects of 24 months of 0.21 IU/kg per week recombinant growth hormone (rh-GH) on the lipoprotein profiles of 22 GH-deficient adults were studied. Samples were collected after a 12-h fast at baseline and 24 months. Total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, LDL cholesterol, apolipoprotein (apo) A, apo B and apo [a] were determined by routine laboratory methods. LDL particle size was determined by non-denaturing gradient gel electrophoresis. Visceral adiposity was determined by dual energy X-ray absorptiometry (DEXA). Insulin sensitivity was measured in a subset of 17 subjects using a two-stage hyperinsulinaemic-euglycaemic clamp.

Significant reductions were observed in total cholesterol (5.3 ± 0.17 vs 4.9 ± 0.23 mmol/l;P<0.05) and LDL cholesterol (3.4 ± 0.17 vs 2.9 ± 0.17 mmol/l;P<0.001) at 24 months when compared to baseline. No significant changes were observed in triglyceride level, HDL cholesterol level, apo B, apo A and LDL size. A significant increase in apo [a] [160 (96–416) vs 204 (127–534) U/l;P<0.05] was observed which appeared to be dose-dependent. Visceral adiposity was reduced significantly. Insulin sensitivity did not alter significantly.

Replacement for 24 months with rh-GH has a differential effect on the lipid profile with a decrease in LDL, but little effect upon the metabolism of triglyceride-rich lipoproteins, manifested by unchanged triglyceride, HDL cholesterol levels and LDL size, despite the reduction in visceral adiposity. Conversely, apo [a], an independent risk factor for cardiovascular disease was increased. The ultimate effect of GH therapy upon cardiovascular mortality remains to be determined and may be dose-related.

References (55)

  • W.B. Kannell et al.

    Role of lipids and lipoprotein fractions in assessing atherogenesis

    The Framingham Study. Prog Lipid Res

    (1981)
  • D. O’Neal et al.

    Low density lipoprotein particle size in hypopituitary adults receiving conventional hormone replacement therapy

    J Clin End Metab

    (1996)
  • T. Rosen et al.

    Cardiovascular risk factors in adult patients with growth hormone deficiency

    Acta Endo.

    (1993)
  • S.A. Beshyah et al.

    Metabolic abnormalities in growth hormone-deficient adults

    II. Carbohydrate tolerance and lipid metabolism. Endocrinol Metab

    (1994)
  • J-O. Johansson et al.

    High fibrinogen and plasminogen activator inhibitor activity in growth hormone deficient adults

    Arterioscler Thromb

    (1994)
  • S.M. Libber et al.

    Long term follow-up of hypopituitary patients treated with human growth hormone

    Medicine

    (1990)
  • G. Heiss et al.

    Lipoprotein cholesterol distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study

    Circulation

    (1980)
  • M.A. Austin et al.

    Low density lipoprotein subclass patterns and risk of myocardial infarction

    JAMA

    (1988)
  • K.A.S. Al-Shoumer et al.

    Fasting and Postprandial lipid abnormalities in hypopituitary women receiving conventional replacement therapy

    J Clin Endocrinol Metab

    (1997)
  • D.N. O’Neal et al.

    The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis

    J Clin Endocrinol Metab

    (1994)
  • F.L. Hew et al.

    Insulin tolerance test in patients with anterior pituitary hormone deficiency: reduced insulin sensitivity

    Endcrinol Metab

    (1995)
  • F.L. Hew et al.

    Insulin resistance in growth hormone-deficient adults: defects in glucose utilisation and glycogen synthase activity

    J Clin Endocrinol Metab

    (1996)
  • Untreated growth hormone deficiency explains premature mortality in patients with hypopituitarism. Growth Hormone IGF Res

    (1998)
  • M. Christopher et al.

    Defects of insulin action and skeletal muscle glucose disposal in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy

    J Clin Endocrinol Metab

    (1998)
  • W.T. Friedewald et al.

    Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultra-centrifuge

    Clin Chem

    (1972)
  • B.H. Chung et al.

    Single vertical spin density gradient ultracentrifugation

    Methods in Enzymology. Chap 8

    (1986)
  • J.R. Albano et al.

    A sensitive precise radioimmunoassay of serum insulin based on a charcoal separation of bound and free hormone moieties

    Acta Endocrinol (Copenh)

    (1972)
  • Cited by (26)

    • Decreased TNF-α gene expression in periodontal ligature in MSG-obese rats: A possible protective effect of hypothalamic obesity against periodontal disease?

      2012, Archives of Oral Biology
      Citation Excerpt :

      The ARC is responsible for the synthesis of the growth hormone-releasing hormone (GHRH), thus the plasma GH concentration is reduced in MSG-obese rodents.17,18 This hormone has lipolytic activity,28 therefore the accumulation of fat and reduction of the naso-anal length can be partly attributed to the reduction in GH. The plasma concentration of total CHOL was similar between the studied groups, but the neonatal MSG treatment caused an increase in TG and NEFA concentrations in comparison with CTL.

    • Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults

      2008, Metabolism: Clinical and Experimental
      Citation Excerpt :

      Results are also variable regarding other lipid measurements: HDL-C levels have increased after GH therapy in some studies [12,14,23,47] but not in others [14,16,26,48,49], whereas mean serum TG concentration was reduced [14,50] or unchanged [12,16,23,26,48,49,51] after GH treatment. Lastly, Lp(a) levels increased in most studies [49-51] but not in all [54-56]. The highly atherogenic apo B, the principal protein component of LDL-C, has so far only been under-investigated in GHD patients receiving GH substitution, as well as apo A-1 levels, the major constituent of HDL-C.

    • Management of growth hormone deficiency in adults

      2007, Growth Hormone and IGF Research
    View all citing articles on Scopus
    View full text